Search results
Results from the WOW.Com Content Network
Inovio Pharmaceuticals (NASDAQ: INO) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p ... and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 ...
The stock of Inovio Pharmaceuticals (NAS:INO, 30-year Financials) shows every sign of being fairly valued, according to GuruFocus Value calculation.
If there's one thing that traders have learned about Inovio Pharmaceuticals (NASDAQ:INO) stock, it's that half a year can make a huge difference. Biotechnology stocks can be fast movers, sure, but ...
[7] [18] Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June. [5] In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800. [19]
A Q2 update about the progress of a late-stage clinical study provides a nice boost to the clinical-stage biotech stock. Why Inovio Pharmaceuticals, Inc. Stock Is Jumping 12.4% Today Skip to main ...
On Friday, shares of Inovio Pharmaceuticals (NASDAQ: INO) saw unusual options activity. After the option alert, the stock price moved up to $15.5. * Sentiment: BEARISH * Option Type: SWEEP * Trade ...
Investors are not impressed with the biotech's latest plan to raise cash.
On 26 August 2021 Inovio's global Phase 3 efficacy trial receives authorization to proceed from Brazil. [10] On 26 October 2021 The World Health Organization launched a Global Covid-19 Trial termed as the Solidarity Trial Vaccines. Inovio INO-4800 was chosen as the first DNA Vaccine to be introduced in the largest vaccine trial in history.